Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Renal Cancer Targeted Therapies with Tyrosine Kinase Inhibitors

  • Egbert OosterwijkEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6327-2


Tyrosine kinase inhibitors (TKIs) are drugs that interfere with cell communication and growth and may prevent tumor growth.


Until recently, patients with metastatic renal cell carcinoma (RCC) were treated with interferon-α, interleukin 2, or combinations thereof. Unfortunately, these agents had limited efficacy and response rates remained low (∼10–15 %). For patients not responding to first-line cytokine therapy, no option for treatment was available. With our increased understanding of the molecular defects that are at the heart of RCC subtypes, new treatment modalities specifically targeting these pathways have been explored. This has led to a revolution in the treatment of RCC. Nevertheless, although improvement is significant, it is still modest and mostly concerns improvement of 2–6 months of progression-free survival.

The most prominent feature of clear-cell RCC (renal carcinoma) is the upregulation of the angiogenic molecule vascular endothelial growth...


Vascular Endothelial Growth Factor Renal Cell Carcinoma Tyrosine Kinase Inhibitor Vascular Endothelial Growth Factor Receptor Metastatic Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Chowdhury S, Larkin JM, Gore ME (2008) Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 44:2152–2161CrossRefPubMedGoogle Scholar
  2. Escudier B (2008) Signaling inhibitors in metastatic renal cell carcinoma. Cancer J 14:325–329CrossRefPubMedGoogle Scholar
  3. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13:1084–1096CrossRefPubMedGoogle Scholar
  4. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601–5608CrossRefPubMedGoogle Scholar
  5. Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 6:835–846CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Laboratory of Experimental UrologyUniversity Medical Centre NijmegenNijmegenThe Netherlands